vs
CollPlant Biotechnologies Ltd（CLGN）与Enovis CORP（ENOV）财务数据对比。点击上方公司名可切换其他公司
Enovis CORP的季度营收约是CollPlant Biotechnologies Ltd的3066.5倍（$548.9M vs $179.0K）。Enovis CORP净利率更高（-104.1% vs -1869.8%，领先1765.8%）。Enovis CORP同比增速更快（-2.2% vs -28.1%）
CollPlant Biotechnologies是一家再生医疗企业，依托专有的植物源人胶原蛋白技术，开发并商业化伤口护理、软组织修复、医美领域的创新产品，主要面向北美、欧洲及以色列市场，服务皮肤科、骨科和医美领域的医疗从业者。
Enovis是一家专注于骨科领域的医疗科技企业，其前身是1995年由米切尔·雷尔斯和史蒂文·雷尔斯兄弟创立的科尔法克斯公司。公司总部位于特拉华州威尔明顿，目前在全球12个地点开展业务，拥有超过5000名员工，于纽约证券交易所上市，股票代码为ENOV。
CLGN vs ENOV — 直观对比
营收规模更大
ENOV
是对方的3066.5倍
$179.0K
营收增速更快
ENOV
高出26.0%
-28.1%
净利率更高
ENOV
高出1765.8%
-1869.8%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $179.0K | $548.9M |
| 净利润 | $-3.3M | $-571.1M |
| 毛利率 | -3.9% | 59.9% |
| 营业利润率 | -1775.4% | -101.7% |
| 净利率 | -1869.8% | -104.1% |
| 营收同比 | -28.1% | -2.2% |
| 净利润同比 | 20.5% | 18.8% |
| 每股收益（稀释后） | $0.28 | $-9.99 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLGNENOV
| Q4 25 | — | $548.9M | ||
| Q3 25 | — | $564.5M | ||
| Q2 25 | $179.0K | $558.8M | ||
| Q4 24 | — | $561.0M | ||
| Q3 24 | — | $505.2M | ||
| Q2 24 | $249.0K | $525.2M | ||
| Q1 24 | — | $516.3M | ||
| Q4 23 | — | $455.0M |
净利润CLGNENOV
| Q4 25 | — | $-571.1M | ||
| Q3 25 | — | $-36.7M | ||
| Q2 25 | $-3.3M | $-56.0M | ||
| Q4 24 | — | $-703.2M | ||
| Q3 24 | — | $-31.5M | ||
| Q2 24 | $-4.2M | $-18.6M | ||
| Q1 24 | — | $-72.0M | ||
| Q4 23 | — | $3.1M |
毛利率CLGNENOV
| Q4 25 | — | 59.9% | ||
| Q3 25 | — | 59.3% | ||
| Q2 25 | -3.9% | 59.5% | ||
| Q4 24 | — | 54.8% | ||
| Q3 24 | — | 56.7% | ||
| Q2 24 | -115.3% | 55.0% | ||
| Q1 24 | — | 57.7% | ||
| Q4 23 | — | 58.1% |
营业利润率CLGNENOV
| Q4 25 | — | -101.7% | ||
| Q3 25 | — | -3.0% | ||
| Q2 25 | -1775.4% | -8.4% | ||
| Q4 24 | — | -118.5% | ||
| Q3 24 | — | -6.3% | ||
| Q2 24 | -1769.5% | -8.4% | ||
| Q1 24 | — | -6.8% | ||
| Q4 23 | — | -1.3% |
净利率CLGNENOV
| Q4 25 | — | -104.1% | ||
| Q3 25 | — | -6.5% | ||
| Q2 25 | -1869.8% | -10.0% | ||
| Q4 24 | — | -125.4% | ||
| Q3 24 | — | -6.2% | ||
| Q2 24 | -1690.8% | -3.5% | ||
| Q1 24 | — | -13.9% | ||
| Q4 23 | — | 0.7% |
每股收益（稀释后）CLGNENOV
| Q4 25 | — | $-9.99 | ||
| Q3 25 | — | $-0.64 | ||
| Q2 25 | $0.28 | $-0.98 | ||
| Q4 24 | — | $-12.69 | ||
| Q3 24 | — | $-0.58 | ||
| Q2 24 | $0.37 | $-0.34 | ||
| Q1 24 | — | $-1.32 | ||
| Q4 23 | — | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.4M | $33.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $12.5M | $2.0B |
| 总资产 | $17.4M | $4.4B |
| 负债/权益比越低杠杆越低 | — | 0.67× |
8季度趋势，按日历期对齐
现金及短期投资CLGNENOV
| Q4 25 | — | $33.6M | ||
| Q3 25 | — | $44.1M | ||
| Q2 25 | $11.4M | $38.5M | ||
| Q4 24 | — | $48.2M | ||
| Q3 24 | — | $35.4M | ||
| Q2 24 | $18.9M | $35.0M | ||
| Q1 24 | — | $66.3M | ||
| Q4 23 | — | $36.2M |
总债务CLGNENOV
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.4B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B | ||
| Q1 24 | — | $1.3B | ||
| Q4 23 | — | $466.2M |
股东权益CLGNENOV
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | $12.5M | $2.6B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | $20.7M | $3.3B | ||
| Q1 24 | — | $3.3B | ||
| Q4 23 | — | $3.4B |
总资产CLGNENOV
| Q4 25 | — | $4.4B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | $17.4M | $4.9B | ||
| Q4 24 | — | $4.7B | ||
| Q3 24 | — | $5.6B | ||
| Q2 24 | $26.6M | $5.4B | ||
| Q1 24 | — | $5.5B | ||
| Q4 23 | — | $4.5B |
负债/权益比CLGNENOV
| Q4 25 | — | 0.67× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.53× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.41× | ||
| Q1 24 | — | 0.40× | ||
| Q4 23 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $82.6M |
| 自由现金流经营现金流 - 资本支出 | — | $29.1M |
| 自由现金流率自由现金流/营收 | — | 5.3% |
| 资本支出强度资本支出/营收 | — | 9.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $22.8M |
8季度趋势，按日历期对齐
经营现金流CLGNENOV
| Q4 25 | — | $82.6M | ||
| Q3 25 | — | $47.8M | ||
| Q2 25 | — | $-1.6M | ||
| Q4 24 | — | $88.3M | ||
| Q3 24 | — | $53.6M | ||
| Q2 24 | — | $7.8M | ||
| Q1 24 | — | $-36.2M | ||
| Q4 23 | — | $68.4M |
自由现金流CLGNENOV
| Q4 25 | — | $29.1M | ||
| Q3 25 | — | $3.4M | ||
| Q2 25 | — | $-44.9M | ||
| Q4 24 | — | $35.1M | ||
| Q3 24 | — | $2.4M | ||
| Q2 24 | — | $-31.6M | ||
| Q1 24 | — | $-73.1M | ||
| Q4 23 | — | $40.5M |
自由现金流率CLGNENOV
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | -8.0% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | -6.0% | ||
| Q1 24 | — | -14.2% | ||
| Q4 23 | — | 8.9% |
资本支出强度CLGNENOV
| Q4 25 | — | 9.7% | ||
| Q3 25 | — | 7.9% | ||
| Q2 25 | — | 7.7% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 10.1% | ||
| Q2 24 | — | 7.5% | ||
| Q1 24 | — | 7.2% | ||
| Q4 23 | — | 6.1% |
现金转化率CLGNENOV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 22.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLGN
暂无分部数据
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
